Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.7100 (8.61%) ($8.9800 - $9.9100) on Mon. Mar. 30, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.11% (three month average) | RSI | 56 | Latest Price | $9.7100(8.61%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 2.2% a day on average for past five trading days. | Weekly Trend | FOLD advances 10.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(55%) XBI(52%) IWO(50%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -3.555% in a week (0% probabilities). VIXM(-27%) VXX(-15%) UUP(-11%) TLT(-5%) UNG(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.555% (StdDev 7.11%) | Hourly BBV | 0 () | Intraday Trend | 7.1% | | | |
|
5 Day Moving Average | $9.47(2.53%) | 10 Day Moving Average | $9.02(7.65%) | 20 Day Moving Average | $8.76(10.84%) | To recent high | -13% | To recent low | 46.5% | Market Cap | $2.507b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |